IL5RA and Increased total eosinophil count: Given that for the targeting of IL-5Rα, only benralizumab has been clinically approved so far, alternative Abs are needed to give physicians the option of switching between anti–IL-5Rα Abs in the management of treatment-refractory SEA and other eosinophilia-related diseases.